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Nucleoside RT inhibitors (NRTIs) are among the most potent anti-HIV agents and act as chain 
terminators because they lack a 3’OH. However, this feature can reduce affinity for RT compared to the 
analogous dNTP substrate, as well as reduced intracellular conversion to the active dNTP. To overcome 
this, it was shown that certain nucleosides that retain the 3’OH and have substitutions at the 4’ ribose and 
2 position of the base have exceptional antiviral properties. One of these compounds, 4’-ethynyl, 2-fluoro 
deoxy-adenosine (4’E-2FdA) is the most potent NRTI inhibitor against wild-type and multi-drug resistant 
HIV viruses described to date. We have recently reported that 4’E-2FdA acts as a chain terminator despite 
the presence of an accessible 3’OH. We show that after 4’E-2FdA-MP incorporation, RT does not bind 
the next incoming dNTP. We analyzed RT translocation on different sequences terminated with 4’E-
2FdA-MP, and found that even at sequences when RT is naturally found post-translocated, the inhibitor 
prevents translocation. This decrease in translocation efficiency explains the reduced binding of the next 
incoming dNTP and the termination of elongation. While the inhibitor stabilizes the pre-translocated 4’E-
2FdA-MP-terminated primer, the pyrophosphate-dependent excision rate of 4’E-2FdA-MP was not very 
high compared to ddAMP. In conclusion, this highly potent chain termination activity arises from 
difficulty of the primer 3’-terminus to translocate following incorporation of the compound, and not from 
simple steric hindrance due to the 4’ substitution. Therefore, we propose that 4’E-2FdA is a 
Translocation-Deficient Reverse Transcriptase Inhibitor (TDRTI) that acts by a novel mechanism.  
 
